Keck School Faculty

Gino In

Gino In

Assistant Professor of Clinical Medicine
Medicine
NOR 3440 NTT Health Sciences Campus Los Angeles

Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions Cancers (Basel). 2022 Mar 15; 14(6). . View in PubMed

Development of a core outcome set for basal cell carcinoma J Am Acad Dermatol. 2022 09; 87(3):573-581. . View in PubMed

Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study Clin Breast Cancer. 2022 06; 22(4):e558-e566. . View in PubMed

Examining low rates of dermatology visits in solid organ transplant recipients J Am Acad Dermatol. 2022 06; 86(6):1369-1372. . View in PubMed

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma J Immunother Cancer. 2022 05; 10(5). . View in PubMed

Disparities in nonmelanoma skin cancer in Hispanic/Latino patients based on Mohs micrographic surgery defect size: A multicenter retrospective study J Am Acad Dermatol. 2022 02; 86(2):353-358. . View in PubMed

Social networks of oncology clinicians as a means for increasing survivorship clinic referral Commun Med (Lond). 2022; 2:89. . View in PubMed

18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma Clin Nucl Med. 2021 Aug 01; 46(8):e436-e437. . View in PubMed

PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California J Cancer Res Clin Oncol. 2021 Jun; 147(6):1803-1811. . View in PubMed

A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma Cureus. 2021 Jun; 13(6):e15480. . View in PubMed

The time to offer treatments for COVID-19 Expert Opin Investig Drugs. 2021 May; 30(5):505-518. . View in PubMed

COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study Endocr Pract. 2021 Feb; 27(2):90-94. . View in PubMed

Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015 Pigment Cell Melanoma Res. 2021 11; 34(6):1049-1061. . View in PubMed

Cutaneous Malignancies of the Head and Neck Hematol Oncol Clin North Am. 2021 10; 35(5):991-1008. . View in PubMed

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database Exp Biol Med (Maywood). 2021 01; 246(1):31-39. . View in PubMed

Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center Cancer Treat Res Commun. 2021; 26:100273. . View in PubMed

Rapidly Progressive Porocarcinoma of the Ear and Multidisciplinary Approach to Management Dermatol Surg. 2021 03 01; 47(3):404-406. . View in PubMed

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922) Melanoma Res. 2021 04 01; 31(2):162-172. . View in PubMed

Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma Genome Med. 2021 08 16; 13(1):130. . View in PubMed

The Importance of Understanding the Stages of COVID-19 in Treatment and Trials AIDS Rev. 2021 02 08; 23(1):40-47. . View in PubMed

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases Oncotarget. 2020 Aug 18; 11(33):3118-3128. . View in PubMed

Skin cancer and dermatoses in a majority-Hispanic population of solid organ transplant recipients J Am Acad Dermatol. 2020 Aug; 83(2):607-610. . View in PubMed

Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study Pediatr Blood Cancer. 2020 03; 67(3):e28090. . View in PubMed

Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease Cancer Med. 2020 02; 9(4):1441-1450. . View in PubMed

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma Int Ophthalmol Clin. 2020; 60(2):77-89. . View in PubMed

Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma JAAD Case Rep. 2019 Sep; 5(9):763-766. . View in PubMed

Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation BMJ Case Rep. 2019 Jun 20; 12(6). . View in PubMed

Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center Dermatol Surg. 2019 02; 45(2):254-267. . View in PubMed

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance Nat Commun. 2019 04 12; 10(1):1693. . View in PubMed

Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma JAAD Case Rep. 2018 Nov; 4(10):1004-1006. . View in PubMed

Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature Dermatol Surg. 2018 10; 44(10):1247-1261. . View in PubMed

Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer Converg Sci Phys Oncol. 2017 Sep; 3(3). . View in PubMed

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. . View in PubMed

Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer Convergent Science Physical Oncology. 2017; 3(3). . View in PubMed

Skin Cancer Prevention Among Hispanics: a Review of the Literature Epidemiology. 2017. . View in PubMed

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies Urol Clin North Am. 2015 Aug; 42(3):347-57. . View in PubMed

Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer Transl Cancer Res. 2015; 4(4):340-355. . View in PubMed

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.
sc ctsi logoPowered by SC CTSI